eLife reviews preprints in the life sciences and medicine.

About Followers

Latest preprint reviews

  1. Low-dose chemotherapy combined with delayed immunotherapy in the neoadjuvant treatment of non-small cell lung cancer and dynamic monitoring of the drug response in peripheral blood

    1. Chaoyang Liang
    2. Qi Song
    3. Wenhao Zhou
    4. Na Li
    5. Qi Xiong
    6. Chaohu Pan
    7. Shaohong Zhao
    8. Xiang Yan
    9. Xiaoling Zhang
    10. Yaping Long
    11. Juntang Guo
    12. Tao Wang
    13. Weiwei Shi
    14. Shengjie Sun
    15. Bo Yang
    16. Zhouhuan Dong
    17. Haitao Luo
    18. Jie Li
    19. Yi Hu
    20. Bo Yang

    • Curated by eLife

      eLife Assessment

      Liang et al. have conducted a small pilot study investigating the feasibility and tolerability of a regimen of neoadjuvant chemo-immunotherapy for non-small cell lung cancer, with lower cumulative dose of chemotherapy and with the immunotherapy delivered on D8 of each cycle. The clinical data are interesting and novel, and overall the findings of the study are valuable. However, the translational data and analyses are incomplete and do not support key claims in the title.

    Reviewed by eLife

    7 evaluationsAppears in 1 listLatest version Latest activity

  5. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

    1. Sander Frank
    2. Thomas Persse
    3. Ilsa Coleman
    4. Armand Bankhead
    5. Dapei Li
    6. Navonil De-Sarkar
    7. Divin Wilson
    8. Dmytro Rudoy
    9. Manasvita Vashisth
    10. Patty Galipeau
    11. Michael Yang
    12. Brian Hanratty
    13. Ruth Dumpit
    14. Colm Morrissey
    15. Eva Corey
    16. R Bruce Montgomery
    17. Michael C Haffner
    18. Colin C Pritchard
    19. Valeri Vasioukhin
    20. Gavin Ha
    21. Peter S Nelson

    • Curated by eLife

      eLife Assessment

      The paper is a fundamental study examining the role of CDK12 loss in prostate cancer. While previous studies have suggested that CDK12 loss confers HRD phenotypes, clinical trials using PARPi in CDK12 altered patients have not demonstrated significant benefit. This work investigates these mechanisms in depth and provides compelling evidence. A comprehensive genomic analysis serves an excellent resource to the field, showing that biallelic CDK12 alterations do not have genomic features of HRd. Moreover, the study explored both acute and chronic deletion of CDK12, with data suggestive of CDK12-altered cells being uniquely sensitive to CDK13 inhibition. While some minor weaknesses have been previously noted by the reviewers, the authors have adequately addressed these concerns with appropriate rigor.

    Reviewed by eLife

    14 evaluationsAppears in 1 listLatest version Latest activity

  7. Bone inflammation in postmenopausal women with type 2 diabetes or obesity in relation to Wnt signaling and bone strength

    1. Giulia Leanza
    2. Malak Faraj
    3. Francesca Cannata
    4. Viola Viola
    5. Niccolò Pellegrini
    6. Flavia Tramontana
    7. Claudio Pedone
    8. Gianluca Vadalà
    9. Alessandra Piccoli
    10. Rocky Strollo
    11. Francesca Zalfa
    12. Lorenzo Nevi
    13. Simone Carotti
    14. Roberto Civitelli
    15. Mauro Maccarrone
    16. Rocco Papalia
    17. Nicola Napoli

    • Curated by eLife

      eLife Assessment

      This is a convincing paper that addresses topics important in our understanding of how inflammatory markers are modulated in both obesity and type 2 diabetes and their effects on Wnt signaling mediators in human bone. There are changes in bone at the tissue level in these 2 common metabolic disorders that ultimately lead to compromised bone strength. These data will be critical to our understanding of the pathophysiology of skeletal fragility in obesity and diabetes.

    Reviewed by eLife

    4 evaluationsAppears in 1 listLatest version Latest activity
Newer Page 207 of 869 Older